CN109614824A - A kind of drug data management method, device and server based on block chain - Google Patents
A kind of drug data management method, device and server based on block chain Download PDFInfo
- Publication number
- CN109614824A CN109614824A CN201811373611.5A CN201811373611A CN109614824A CN 109614824 A CN109614824 A CN 109614824A CN 201811373611 A CN201811373611 A CN 201811373611A CN 109614824 A CN109614824 A CN 109614824A
- Authority
- CN
- China
- Prior art keywords
- block chain
- data information
- drug
- stage
- node
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
- G06F21/60—Protecting data
- G06F21/64—Protecting data integrity, e.g. using checksums, certificates or signatures
Landscapes
- Engineering & Computer Science (AREA)
- Computer Security & Cryptography (AREA)
- Theoretical Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioethics (AREA)
- General Health & Medical Sciences (AREA)
- Computer Hardware Design (AREA)
- Software Systems (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
This application provides a kind of drug data management method, device and servers based on block chain, for solving the problems, such as that current drug data information is dangerous, being easy to be tampered, this method comprises: block chain second node obtains first stage drug data information of the block chain first node encryption publication in block chain network；The block chain second node obtains the second stage drug data information formed according to the first stage drug data information, and by publication after second stage drug data information encryption in block chain network.
Description
Technical field
This application involves block chain technical field of data administration, relate generally to a kind of drug data management based on block chain
Method, apparatus and server.
Background technique
Drug data management method on the market is typically all the LIMS system, Empower system, OpenLAB of being based at present
The management method of the systems such as system, once server occurs abnormal or indicates that systematicness is awarded to routed or company chief executive
Weight update drug data information, causes that drug data information is dangerous, is easy the problems such as being tampered.
Apply for content
Being designed to provide for the application is a kind of based on block chain drug data management method, device and server, is used for
It solves the problems, such as that current drug data information is dangerous, be easy to be tampered.
To achieve the goals above, it is as follows that this application provides following technical schemes:
First aspect: this application provides one kind to be based on block chain drug data management method, which comprises
Block chain second node obtains first stage drug data of the block chain first node encryption publication on block chain
Information；
The block chain second node obtains the second stage drug formed according to the first stage drug data information
Data information, and by publication after second stage drug data information encryption in block chain network.
The method of above scheme design, the drug data information of next stage by block chain node visit on last stage
Drug data information obtains, and is managed using block chain network to drug data information, so that drug data information security
And can not distort, improve the stability and reliability of drug data information.
In the optional implementation of first aspect, the block chain second node obtains block chain first node encryption hair
First stage drug data information of the cloth on block chain, comprising:
The public key acquisition block chain first node that the block chain second node is shared by the block chain first node
Use the first stage drug data information of private key encryption.
The method of above scheme design, carries out encryption reconciliation to the drug data information in block chain by key mechanism
It is close, enable drug data information more safe.
In the optional embodiment of first aspect, the block chain second node passes through the block chain first node point
The public key acquisition block chain first node enjoyed uses the first stage drug data information of private key encryption, comprising:
Elliptic curve encryption algorithm is carried out to the private key and generates corresponding public key, it is raw to carry out hash algorithm to the public key
At public key Hash, the access address that coding obtains the first stage drug data information is carried out to the public key Hash.
In the optional embodiment of first aspect, the block chain second node believes the second stage drug data
Publication is in block chain network after encryption for information, comprising:
The block chain second node uses the private key to second stage drug data by generating random number private key
Publication is in block chain network after information is encrypted.
The method of above scheme design, is encrypted and decrypted drug data information by symmetric key encryption mechanism,
So that encryption/decryption speed is fast.
In the optional embodiment of first aspect, the method also includes:
The block chain second node obtains the user's signature of second stage drug data information described in typing, and will be described
User's signature is issued in block chain network.
The method of above scheme design, obtains the signature of the user of typing drug data information, so that drug data information
Source can be tracked, once discovery drug data information data fabrication, promptly and accurately can find fake producer.
In the optional embodiment of first aspect, in the block chain second node by the second stage drug data
After information is encrypted, the method also includes:
The block chain second node configures in the second stage drug data information and checks claim.
Above scheme design method, configuration check claim make it is subsequent have check that the node of power is able to access that block chain
The second stage drug data information that second node obtains, the node without the power of checking can not check second stage drug number
It is believed that breath, further improves the safety coefficient of drug data.
In the optional embodiment of first aspect, block chain second node obtains the encryption publication of block chain first node and exists
First stage drug data information on block chain, the block chain second node are obtained according to the first stage drug data
The second stage drug data information that information is formed, and by publication after second stage drug data information encryption in block chain
On network, comprising:
The block chain second node obtains development phase drug of the block chain first node encryption publication on block chain
Data information, the block chain second node obtain the drug production phase formed according to the development phase drug data information
Data information, and by publication after drug production phase data information encryption in block chain network；Or
The block chain second node obtains drug production phase of the block chain first node encryption publication on block chain
Data information, the block chain second node acquisition put goods on the market according to the drug that the drug production phase data information is formed
Phase data information, and the drug is put goods on the market after phase data information encrypts and is issued in block chain network.
In the optional embodiment of first aspect, the medicament research and development stage drug data information includes: drug early period
Investigation phase data information sets up drug project stage data information, drug prescription process exploitation phase data information, at drug
Square process exploitation phase data information, drug enlarged experiment data information and process certification data information；The drug production
Stage drug data information includes: that drug supplementary material procurement data information, drug supplementary material examine clearance data information, drug to match
Expect data information, the filling data information of drug, drug packages data information, drug test clearance data information.
Second aspect: this application provides a kind of drug data managing device based on block chain, described device includes:
Module is obtained, for obtaining first stage drug data letter of the block chain first node encryption publication on block chain
Breath；And obtain the second stage drug data information formed according to the first stage drug data information；
Encrypting module, the second stage drug data information for obtaining to the acquisition module encrypt；
Release module, the second stage drug data information for encrypting the encrypting module are issued in block chain network
On.
The device of above scheme design, the drug data information of next stage by block chain node visit on last stage
Drug data information obtains, and is managed using block chain network to drug data information, so that drug data information security
And can not distort, improve the stability and reliability of drug data information.
In the optional embodiment of second aspect,
The acquisition module is also used to block chain first node described in the public key acquisition by the sharing of block chain first node
Use the first stage drug data information of private key encryption.
In the optional embodiment of second aspect, second stage medicine of the encrypting module to the acquisition module acquisition
Object data information is encrypted, comprising:
The encrypting module by generating random number private key, and using the private key to second stage drug data information into
Row encryption.
In the optional embodiment of second aspect, the acquisition module is also used to obtain second stage medicine described in typing
The user's signature of object data information；
The release module is also used to issue the user's signature that the acquisition module obtains in block chain network.
The third aspect: the application provides a kind of server, comprising: processor, and storage connected to the processor respectively
Device and transceiver, the memory are stored with the executable machine readable instructions of the processor, the transceiver be used for it is outer
Portion's equipment carries out communications；When server operation, the processor executes the machine readable instructions, when executing
Execute the method in any optional implementation of first aspect, first aspect.
Fourth aspect: the application provides a kind of non-transient computer readable storage medium, the computer readable storage medium
On be stored with computer program, when which is run by processor execute first aspect, first aspect it is any optional
Implementation in the method.
5th aspect: the application provides a kind of computer program product, and the computer program product is transported on computers
When row, so that computer executes the method in any optional implementation of first aspect, first aspect.
The beneficial effect of the application include: the application obtain by above-mentioned design based on block chain drug data manager
Method, device and server, drug data letter of the drug data information of next stage by block chain node visit on last stage
Breath is managed drug data information using block chain network to obtain, so that drug data information security and can not distort,
Improve the stability and reliability of drug data information.
Other feature and advantage of the application will be illustrated in subsequent specification, also, partly be become from specification
It is clear that being understood and implementing the embodiment of the present application.The purpose of the application and other advantages can be by written
Specifically noted structure is achieved and obtained in specification, claims and attached drawing.
Detailed description of the invention
In order to illustrate the technical solutions in the embodiments of the present application or in the prior art more clearly, below will be to institute in embodiment
Attached drawing to be used is needed to be briefly described, it should be apparent that, the accompanying drawings in the following description is only some implementations of the application
Example, for those of ordinary skill in the art, without creative efforts, can also obtain according to these attached drawings
Obtain other attached drawings.By the way that shown in attached drawing, above and other purpose, the feature and advantage of the application will be more clear.In whole
Identical appended drawing reference indicates identical part in attached drawing.Attached drawing, emphasis deliberately are not drawn by actual size equal proportion scaling
It is that the purport of the application is shown.
Fig. 1 is the offer of the application first embodiment based on block chain drug data management method flow diagram；
Fig. 2 is the offer of the application second embodiment based on block chain drug data managing device structural schematic diagram；
Fig. 3 is the server architecture schematic diagram that the application 3rd embodiment provides.
Specific embodiment
To keep the purposes, technical schemes and advantages of the application embodiment clearer, implement below in conjunction with the application
The technical solution in the application embodiment is clearly and completely described in attached drawing in mode, it is clear that described reality
The mode of applying is a part of embodiment of the application, rather than whole embodiments.Based on the embodiment in the application, ability
Domain those of ordinary skill every other embodiment obtained without creative efforts, belongs to the application
The range of protection.Therefore, the detailed description of the presently filed embodiment provided in the accompanying drawings is not intended to limit below and is wanted
The scope of the present application of protection is sought, but is merely representative of the selected embodiment of the application.Based on the embodiment in the application,
Every other embodiment obtained by those of ordinary skill in the art without making creative efforts belongs to this
Apply for the range of protection.
In the description of the present application, it is to be understood that term " center ", " length ", " width ", " thickness ", "upper",
The orientation or positional relationship of the instructions such as "lower", "front", "rear", "left", "right", "inner", "outside" is orientation based on the figure
Or positional relationship, it is merely for convenience of description the application and simplifies description, rather than the equipment or element of indication or suggestion meaning
It must have a particular orientation, be constructed and operated in a specific orientation, therefore should not be understood as the limitation to the application.
In addition, term " first ", " second " etc. are used for description purposes only, it is not understood to indicate or imply relatively important
Property or implicitly indicate the quantity of indicated technical characteristic.The feature for defining " first ", " second " etc. as a result, can be expressed
Or implicitly include one or more of the features.In the description of the present application, the meaning of " plurality " is two or two
More than, unless otherwise specifically defined.
In this application unless specifically defined or limited otherwise, term " installation ", " connected ", " connection ", " fixation " etc.
Term shall be understood in a broad sense, for example, it may be being fixedly connected, may be a detachable connection, or integral；It can be direct phase
Even, can also indirectly connected through an intermediary, the interaction that can be connection or two elements inside two elements is closed
System.For the ordinary skill in the art, above-mentioned term in this application specific can be understood as the case may be
Meaning.
In this application unless specifically defined or limited otherwise, fisrt feature second feature "upper" or "lower"
It may include that the first and second features directly contact, also may include that the first and second features are not direct contacts but pass through it
Between other characterisation contact.Moreover, fisrt feature includes the first spy above the second feature " above ", " above " and " above "
Sign is right above second feature and oblique upper, or is merely representative of first feature horizontal height higher than second feature.Fisrt feature exists
Second feature " under ", " lower section " and " following " include that fisrt feature is directly below and diagonally below the second feature, or is merely representative of
First feature horizontal height is less than second feature.
First embodiment
As shown in Figure 1, the application provides one kind based on block chain drug data management method, this method comprises:
Step 101: block chain second node obtains the of publication after the encryption of block chain first node in block chain network
One stage drug data information, goes to step 102.
Step 102: block chain second node obtains the second stage drug formed according to first stage drug data information
Data information goes to step 103.
Step 103: block chain second node encrypts second stage drug data information, goes to step 104.
Step 104: block chain second node issues encrypted second stage drug data information in block chain network
On.
For the above method, herein it should be noted that second stage drug data information is first stage drug number
It is believed that the latter half of breath, such as first stage drug data information are development phase drug data information, then second stage is
Drug production phase data information after researching and developing successfully.
For step 102, what needs to be explained here is that, block chain second node is obtained to be believed according to first stage drug data
The second stage drug data information formed is ceased, there is following two mode: first, block chain second node accesses in first node
First stage drug data information after, the staff of second stage is just according to the first rank on this block chain second node
Section drug data information generates second stage drug data information.
Second, after block chain second node obtains first stage drug data information, first stage drug data is believed
Breath is sent to the staff of second stage, and the staff of second stage passes through it according to the drug data information of first stage
His mode obtains second stage drug data information, then by typing block chain second node, to carry out obtaining second stage medicine
Object data information.
The method of above scheme design, the drug data information of next stage by block chain node visit on last stage
Drug data information obtains, and is managed using block chain network to drug data information, so that drug data information security
And can not distort, improve the stability and reliability of drug data information.
Optionally, the encryption publication of block chain first node is obtained in block link network for step 101 block chain second node
First stage drug data information on network, comprising: the public affairs that block chain second node is shared by the block chain first node
Key obtains the first stage drug data information that block chain first node uses private key encryption.
Specifically, block chain first node encrypts first stage drug data information by private key, comprising: pass through
Generating random number private key encrypts data information using the private key of generation；
Block chain second node accesses the first stage of block chain first node encryption by the corresponding public key of the private key
Drug data information, comprising: elliptic curve encryption algorithm is carried out to private key and generates corresponding public key, hash algorithm is carried out to public key
Public key Hash is generated, the access address that coding obtains first stage drug data information is carried out to public key Hash.
The method of above scheme design, carries out encryption reconciliation to the drug data information in block chain by key mechanism
It is close, enable drug data information more safe.
Optionally, this method further include: block chain second node also obtains the use of typing second stage drug data information
Family signature, and by user's signature publication in block chain network.
In addition, likewise, further including publication typing after block chain first node publication first stage drug data information
The user's signature of first stage drug data information, that is to say, that after the drug data in each stage obtains, all acquisition typings should
The user of stage drug data or perhaps the signature of responsible person.
The method of above scheme design, obtains the signature of the user of typing drug data information, so that drug data information
Source can be tracked, once discovery drug data information data fabrication, promptly and accurately can find fake producer.
Optionally, after step 103 block chain second node encrypts the second stage drug data information,
This method further include: block chain second node configures in second stage drug data information and checks claim.
Check that the nodal community of claim can specifically, having are as follows: the corresponding area of monitoring personnel of the drug data in full stage
The monitoring node of block chain, or need to use the drug data in this stage and then carry out personnel's correspondence of drug next stage operation
Node, or the corresponding block chain node of any one personnel with claim.
Above scheme design method, configuration check claim make it is subsequent have check that the node of power is able to access that block chain
The second stage drug data information that second node obtains, can not access without the block chain node for checking claim and check this
The drug data information in stage, so that the safety of drug data is greatly improved.
In the scheme of the application, the major class in stage can specifically: when the first stage is development phase, block chain first segment
The first stage drug data information that point obtains is medicament research and development phase data information, then second stage is the drug production phase,
The second stage drug data information that block chain second node obtains is drug production phase data information；It is medicine when the first stage
When the object production phase, then the first stage drug data information that block chain first node obtains then is drug production phase data letter
Breath, then second stage is that drug puts goods on the market the stage, and the second stage drug data information that block chain second node obtains is medicine
Object puts goods on the market phase data information.
The stage of each major class can be divided into the stage of multiple groups, and specific development phase includes: investigation early period, stands
Item, formulation and technology exploitation, analysis method exploitation, enlarged experiment and process certification etc..It is to investigate rank early period when the first stage
Section, then the first stage drug data information that block chain first node obtains are to investigate phase data information early period, then second-order
Section is project verification (the setting up project) stage, then the second stage drug data information that block chain second node obtains is to set up project rank
Segment data information；It is to set up the project stage when the first stage, then the first stage drug data letter that block chain first node obtains
Breath is sets up project stage data information, then second stage is the formulation and technology development phase, then block chain second node obtains
Second stage drug data information is formulation and technology development phase data information；It is the formulation and technology development phase when the first stage,
The first stage drug data information that then block chain first node obtains is formulation and technology development phase data information, then second-order
Section is the analysis method development phase, then the second stage drug data information that block chain second node obtains is analysis method exploitation
Phase data information；It is analysis method development phase, then the first stage drug that block chain first node obtains when the first stage
Data information is analysis method development phase data information, then second stage is Chinese style amplification stage, then block chain second node
The second stage drug data information of acquisition is enlarged experiment phase data information；It is the enlarged experiment stage when the first stage, then
The first stage drug data information that block chain first node obtains is enlarged experiment phase data information, then second stage is work
Skill Qualify Phase, then the second stage drug data information that block chain second node obtains are process certification phase data information.
The specific drug production phase includes: supplementary material buying, supplementary material inspection clearance, ingredient, filling, packaging, drug
Detection clearance etc..
It is the supplementary material acquisition phase when the first stage, then the first stage drug data letter that block chain first node obtains
Breath is supplementary material procurement data information, then second stage is that supplementary material examines the clearance stage, then block chain second node obtains
Second stage drug data information is that supplementary material examines clearance data information；It is that supplementary material examines the clearance stage when the first stage,
The first stage drug data information that then block chain first node obtains is that supplementary material examines clearance data information, then second stage
For dispensing stage, then the second stage drug data information that block chain second node obtains is ingredient data information；When the first rank
Section is dispensing stage, then the first stage drug data information that block chain first node obtains is ingredient data information, then second
Stage is the filling stage, then the second stage drug data information that block chain second node obtains is filling data information；When
One stage was the filling stage, then the first stage drug data information that block chain first node obtains is filling data information, then
Second stage is packing stage, then the second stage drug data information that block chain second node obtains is packaged data information；
When the first stage be packing stage, then block chain first node obtain first stage drug data information be number of package it is believed that
Breath, then second stage is that drug abuse test is let pass the stage, then the second stage drug data information that block chain second node obtains is
Drug abuse test clearance data information.
In above scheme, the data of next stage all can be by accessing drug data information acquisition on last stage.
Second embodiment
As shown in Fig. 2, the application also provides a kind of drug data managing device based on block chain, comprising:
Module 201 is obtained, for obtaining first stage drug number of the block chain first node encryption publication on block chain
It is believed that breath；And the second stage drug data information formed according to the first stage drug data information；
Encrypting module 202, for being encrypted to the second stage drug data information for obtaining the acquisition of module 201；
Release module 203, the second stage drug data information for encrypting encrypting module 202 are issued in block link network
On network.
The device of above scheme design, the drug data information of next stage by block chain node visit on last stage
Drug data information obtains, and is managed using block chain network to drug data information, so that drug data information security
And can not distort, improve the stability and reliability of drug data information.
In the optional embodiment of second embodiment, module 201 is obtained, is also used to share by block chain first node
Public key acquisition block chain first node use private key encryption first stage drug data information.
The device of above scheme design, carries out encryption reconciliation to the drug data information in block chain by key mechanism
It is close, enable drug data information more safe.
In the optional embodiment of second embodiment, 202 pairs of encrypting module obtain the second stage medicine that module 201 obtains
Object data information is encrypted, comprising:
Encrypting module 202 adds second stage drug data information using private key by generating random number private key
It is close.
In the optional embodiment of second embodiment, module 201 is obtained, is also used to obtain typing second stage drug number
It is believed that the user's signature of breath；
Release module 203, the user's signature for being also used to will acquire the acquisition of module 201 are issued in block chain network.
The device of above scheme design, obtains the signature of the user of typing drug data information, so that drug data information
Source can be tracked, once discovery drug data information data fabrication, promptly and accurately can find fake producer.
3rd embodiment
As shown in figure 3, the application provides a kind of server, comprising: processor 301, and it is connected to the processor respectively
Memory 302 and transceiver 303, memory 302 are stored with the executable machine readable instructions of processor 301, and transceiver 303 is used
In with external equipment carry out communications；When calculating equipment operation, processor 301 executes the machine readable instructions,
The method in any optional implementation of first embodiment, first embodiment is executed when executing.
The application provides a kind of non-transient computer readable storage medium, deposits in the non-transient computer readable storage medium
Contain computer program, when which is run by processor execute first embodiment, first embodiment it is any optional
Implementation in the method.
The application provides a kind of computer program product, when the computer program product is run on computers, so that
The method that computer executes in any optional implementation of first embodiment, first embodiment is set.
The above, the only specific embodiment of the application, but the protection scope of the application is not limited thereto, it is any
Those familiar with the art within the technical scope of the present application, can easily think of the change or the replacement, and should all contain
Lid is within the scope of protection of this application.Therefore, the protection scope of the application shall be subject to the protection scope of the claim.
Claims (10)
1. a kind of drug data management method based on block chain, which is characterized in that the described method includes:
Block chain second node obtains first stage drug data of the block chain first node encryption publication in block chain network
Information；
The block chain second node obtains the second stage drug data formed according to the first stage drug data information
Information, and by publication after second stage drug data information encryption in block chain network.
2. method according to claim 1, which is characterized in that the block chain second node obtains block chain first node and adds
First stage drug data information of the close publication on block chain, comprising:
The block chain second node is used by the public key acquisition block chain first node that the block chain first node is shared
The first stage drug data information of private key encryption.
3. method according to claim 1, feature is being, the block chain second node is by the second stage drug
Publication is in block chain network after data information encryption, comprising:
The block chain second node uses the private key to second stage drug data information by generating random number private key
Publication is in block chain network after being encrypted.
4. method according to claim 1, which is characterized in that the method also includes:
The block chain second node obtains the user's signature of second stage drug data information described in typing, and by the user
Signature publication is in block chain network.
5. method according to claim 1, which is characterized in that in the block chain second node by the second stage drug
After data information is encrypted, the method also includes:
The block chain second node configures in the second stage drug data information and checks claim.
6. method according to claim 1, which is characterized in that block chain second node obtains block chain first node encryption hair
First stage drug data information of the cloth on block chain, the block chain second node are obtained according to the first stage drug
The second stage drug data information that data information is formed, and by publication after second stage drug data information encryption in area
In block chain network, comprising:
The block chain second node obtains development phase drug data of the block chain first node encryption publication on block chain
Information, the block chain second node obtain the drug production phase data formed according to the development phase drug data information
Information, and by publication after drug production phase data information encryption in block chain network；Or
The block chain second node obtains drug production phase data of the block chain first node encryption publication on block chain
Information, the block chain second node acquisition put goods on the market the stage according to the drug that the drug production phase data information is formed
Data information, and the drug is put goods on the market after phase data information encrypts and is issued in block chain network.
7. method according to claim 6, which is characterized in that the medicament research and development stage drug data information includes: drug
Investigation early period phase data information sets up drug project stage data information, drug prescription process exploitation phase data information, medicine
Object formulation and technology development phase data information, drug enlarged experiment data information and process certification data information；The drug
Production phase drug data information includes: drug supplementary material procurement data information, drug supplementary material inspection clearance data information, medicine
Object ingredient data information, the filling data information of drug, drug packages data information, drug test clearance data information.
8. a kind of drug data managing device based on block chain, which is characterized in that described device includes:
Module is obtained, for obtaining first stage drug data information of the block chain first node encryption publication on block chain；
And the second stage drug data information formed according to the first stage drug data information；
Encrypting module, the second stage drug data information for obtaining to the acquisition module encrypt；
Release module, the second stage drug data information for encrypting the encrypting module are issued in block chain network.
9. a kind of server, which is characterized in that the server includes: processor, and be connected to the processor respectively
Memory and transceiver,
The memory, for storing the executable machine readable instructions of the processor；
The transceiver, for carrying out communications with external equipment；
The processor, for executing the machine readable instructions, to execute the side as described in any one of claim 1-7
Method.
10. a kind of non-transient computer readable storage medium, which is characterized in that the non-transient computer readable storage medium is deposited
Computer instruction is stored up, the computer instruction makes the computer execute the method as described in any one of claim 1-7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811373611.5A CN109614824A (en) | 2018-11-19 | 2018-11-19 | A kind of drug data management method, device and server based on block chain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811373611.5A CN109614824A (en) | 2018-11-19 | 2018-11-19 | A kind of drug data management method, device and server based on block chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109614824A true CN109614824A (en) | 2019-04-12 |
Family
ID=66004145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811373611.5A Pending CN109614824A (en) | 2018-11-19 | 2018-11-19 | A kind of drug data management method, device and server based on block chain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109614824A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110365475A (en) * | 2019-06-21 | 2019-10-22 | 深圳壹账通智能科技有限公司 | Block chain two-stage monitoring and managing method, device, equipment and storage medium |
| CN111784103A (en) * | 2020-05-22 | 2020-10-16 | 上海飞鱼医疗科技有限公司 | Reagent quality full-process management system based on block chain technology |
| CN112365347A (en) * | 2020-11-12 | 2021-02-12 | 杭州卓健信息科技有限公司 | Medicine research and development clinical medical data safety sharing system based on block chain |
| WO2021128839A1 (en) * | 2019-12-24 | 2021-07-01 | 深圳壹账通智能科技有限公司 | Data entry method and apparatus based on blockchain network, and computer device |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107078910A (en) * | 2016-12-23 | 2017-08-18 | 深圳前海达闼云端智能科技有限公司 | Generate method, device, node, signature device and the system of block chain block |
| CN107154850A (en) * | 2017-05-17 | 2017-09-12 | 北京汇通金财信息科技有限公司 | A kind of processing method and processing device of block chain data |
| CN107294709A (en) * | 2017-06-27 | 2017-10-24 | 阿里巴巴集团控股有限公司 | A kind of block chain data processing method, apparatus and system |
| CN107846278A (en) * | 2017-10-30 | 2018-03-27 | 中国联合网络通信集团有限公司 | Intelligent contract processing method and processing device |
| CN107862215A (en) * | 2017-09-29 | 2018-03-30 | 阿里巴巴集团控股有限公司 | A kind of date storage method, data query method and device |
| CN108449359A (en) * | 2018-04-16 | 2018-08-24 | 济南浪潮高新科技投资发展有限公司 | A kind of electronic health record sharing method and system based on block chain |
-
2018
- 2018-11-19 CN CN201811373611.5A patent/CN109614824A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107078910A (en) * | 2016-12-23 | 2017-08-18 | 深圳前海达闼云端智能科技有限公司 | Generate method, device, node, signature device and the system of block chain block |
| CN107154850A (en) * | 2017-05-17 | 2017-09-12 | 北京汇通金财信息科技有限公司 | A kind of processing method and processing device of block chain data |
| CN107294709A (en) * | 2017-06-27 | 2017-10-24 | 阿里巴巴集团控股有限公司 | A kind of block chain data processing method, apparatus and system |
| CN107862215A (en) * | 2017-09-29 | 2018-03-30 | 阿里巴巴集团控股有限公司 | A kind of date storage method, data query method and device |
| CN107846278A (en) * | 2017-10-30 | 2018-03-27 | 中国联合网络通信集团有限公司 | Intelligent contract processing method and processing device |
| CN108449359A (en) * | 2018-04-16 | 2018-08-24 | 济南浪潮高新科技投资发展有限公司 | A kind of electronic health record sharing method and system based on block chain |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110365475A (en) * | 2019-06-21 | 2019-10-22 | 深圳壹账通智能科技有限公司 | Block chain two-stage monitoring and managing method, device, equipment and storage medium |
| CN110365475B (en) * | 2019-06-21 | 2021-12-10 | 深圳壹账通智能科技有限公司 | Block chain two-stage supervision method, device, equipment and storage medium |
| WO2021128839A1 (en) * | 2019-12-24 | 2021-07-01 | 深圳壹账通智能科技有限公司 | Data entry method and apparatus based on blockchain network, and computer device |
| CN111784103A (en) * | 2020-05-22 | 2020-10-16 | 上海飞鱼医疗科技有限公司 | Reagent quality full-process management system based on block chain technology |
| CN111784103B (en) * | 2020-05-22 | 2024-05-07 | 上海飞鱼医疗科技有限公司 | Reagent quality whole-flow management system based on blockchain technology |
| CN112365347A (en) * | 2020-11-12 | 2021-02-12 | 杭州卓健信息科技有限公司 | Medicine research and development clinical medical data safety sharing system based on block chain |
| CN112365347B (en) * | 2020-11-12 | 2024-06-11 | 杭州卓健信息科技有限公司 | Blockchain-based drug research and development clinical medical data safe sharing system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109614824A (en) | A kind of drug data management method, device and server based on block chain | |
| Hathaliya et al. | Blockchain-based remote patient monitoring in healthcare 4.0 | |
| Dwivedi et al. | Blockchain based secured information sharing protocol in supply chain management system with key distribution mechanism | |
| Wei et al. | Blockchain data-based cloud data integrity protection mechanism | |
| Taloba et al. | A blockchain-based hybrid platform for multimedia data processing in IoT-Healthcare | |
| Inukollu et al. | Security issues associated with big data in cloud computing | |
| US12013813B2 (en) | Regulating distributed network generation of blockchain blocks | |
| Gonçalves et al. | Security architecture for mobile e-health applications in medication control | |
| Rahman et al. | A survey of blockchain-based IoT eHealthcare: Applications, research issues, and challenges | |
| CN107799163A (en) | Prescription circulation methods, devices and systems based on block chain | |
| Dubovitskaya et al. | A cloud-based ehealth architecture for privacy preserving data integration | |
| Agarwal et al. | A systematic analysis of applications of blockchain in healthcare | |
| Donawa et al. | Scaling blockchains to support electronic health records for hospital systems | |
| Abunadi et al. | Blockchain and Business Process Management in Health Care, Especially for COVID‐19 Cases | |
| Ren et al. | Efficient data integrity auditing for storage security in mobile health cloud | |
| Yogeshwar et al. | Healthcare domain in IoT with blockchain based security-A researcher's perspectives | |
| Renardi et al. | Securing electronic medical record in near field communication using advanced encryption standard (AES) | |
| Adsul et al. | A novel approach for traceability & detection of counterfeit medicines through blockchain | |
| Elsayeh et al. | Cybersecurity architecture for the internet of medical things and connected devices using blockchain | |
| Panwar et al. | A cognitive approach for blockchain-based cryptographic curve hash signature (BC-CCHS) technique to secure healthcare data in Data Lake | |
| Bennacer et al. | A comprehensive survey on blockchain-based healthcare industry: Applications and challenges | |
| Jiang et al. | GAIN: Decentralized privacy-preserving federated learning | |
| Praveen et al. | The impact of blockchain on the healthcare environment | |
| Jiamsawat et al. | Blockchain-Based Electronic Medical Records Management of Hospital Emergency Ward | |
| Garg et al. | Blockchain-based electronic health record and open research challenges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190412 |